7x24hNews
BeiGene plans to invest $19.5 million in Bravera's Series A financing round.
2026.11.16 - 10:13
Exclusive
TechFlow reports that on November 16, as reported by Jin10 Data, BeiGene announced that its wholly-owned subsidiary, BeiGene Switzerland, plans to participate alongside the related-party entity Baker Bros and other investors in the Series A financing round of Bravera Bio.
BeiGene Switzerland is expected to make a total cash investment of USD 19.5 million and convert its USD 500,000 SAFE into Series A preferred shares. Upon completion of the transaction, BeiGene Switzerland will hold a 9.477% stake in Bravera.
The transaction constitutes a related-party transaction but does not amount to a major asset restructuring, and therefore does not require approval from the board of directors or the shareholders’ general meeting.
Add to Favorites
Share to Social Media





